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Abstract
Background: Only 5% of the estimated global multidrug resistant TB (MDRTB) load is currently detected. Endemic
Mumbai with increasing MDR would benefit from the introduction of molecular methods to detect resistance.
Methods: The GenoType MTBDRplus assay was used to determine mutations associated with isoniazid and
rifampicin resistance and their correlation with treatment outcomes. It was performed on a convenience sample
comprising 88 onset and 67 fifth month isolates for which phenotypic drug susceptibility testing (DST) was
determined by the Buddemeyer technique for an earlier study. Simultaneous presence of wild type and mutant
bands was referred to as “mixed patterns” (heteroresistance).
Results: Phenotypically 41 isolates were sensitive; 11 isoniazid, 2 rifampicin, 2 pyrazinamide and 5 ethambutol
monoresistant; 16 polyresistant and 78 MDR. The agreement between both methods was excellent (kappa = 0.72-0.92). Of
22 rifampicin resistant onset isolates, the predominant rpoB mutations were the singular lack of WT8 (n = 8) and mixed
D516V patterns (n = 9). Of the 64 rifampicin resistant fifth month isolates, the most frequent mutations were in WT8 (n = 31)
with a further 9 showing the S531L mutation. Mixed patterns were seen in 22 (34%) isolates, most frequently for the D516V
mutation (n = 21). Of the 22 onset and 35 fifth month katG mutants, 13 and 12 respectively showed the S315T1 mutation
with loss of the WT. Mixed patterns involving both S315T1 and S315T2 were seen in 9 and 23 isolates respectively.
Seventeen of 23 and 23/35 inhA mutant onset and fifth month isolates showed mixed A16G profiles. Additionally, 10 fifth
month isolates lacked WT2. Five onset and 6 fifth month isolates had both katG and inhA mutations. An association was
noted between only katG but not only inhA resistance and poor outcome (p = 0.037); and additional resistance to
ethambutol (p = 0.0033). More fifth month than onset isolates had mixed profiles for at least 1 gene (p = 0.000001).
Conclusions: The use of the assay to rapidly diagnose MDR could guide simultaneous first- and second-line DST,
and reduce the delay in administering appropriate regimens. Furthermore, detection of heteroresistance could
prevent inaccurate “cured” treatment outcomes documented through smear microscopy and permit more sensitive
detection of neonascent resistance.
Background
Tuberculosis (TB), a leading cause of death globally,
with increasing rates of drug resistance is of concern.
Timely diagnosis and treatment are the key elements of
the effort to combat TB and reduce transmission by
rendering infectious cases non-infectious.
Only 5% of the World Health Organization (WHO)
estimated global multidrug resistant TB (MDRTB) case
load of 440,000 is currently detected [1,2]. Detection by
conventional drug susceptibility testing (DST) requires
considerable resources of infrastructure and trained per-
sonnel. The WHO recommends the use of MGIT960
and line probe assays (LPAs) towards quicker MDR
detection [3] since phenotypic DST takes 4 to 6 weeks
from the receipt of clinical samples.
* Correspondence: fmr@fmrindia.org
The Foundation for Medical Research., 84A, R. G. Thadani Marg, Worli,
Mumbai 400 018, India
Tolani et al. BMC Infectious Diseases 2012, 12:9
http://www.biomedcentral.com/1471-2334/12/9
© 2012 Tolani et al; BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Commercial and in-house systems for the rapid detec-
tion of rifampicin (RIF) resistant Mycobacterium tubercu-
losis (M. tb)t a k e5 - 8h r sf r o mt h et i m eo fs a m p l e
collection [4,5]. The GenoType MTBDRplus is superior in
that it detects mutations associated with both rifampicin
and isoniazid resistance unlike the INNO-LiPA Rif.TB
(Innogenetics, Belgium) which detects mutations only to
the former. Unlike RIF resistance, in which 95% of isolates
have mutations within an 81-bp region of the rpoB gene
encoding the RNA polymerase b subunit [6], isoniazid
(INH) resistance has been associated with mutations in
several genes [7,8]. Furthermore, since the technique is
polymerase chain reaction (PCR) based, it allows detection
of low levels of resistant bacteria amidst a predominantly
susceptible population, providing a more accurate repre-
sentation of the susceptibility of the infecting bacteria
[9,10]. Different mutations lead to varying degrees of resis-
tance and influence bacterial ability to multiply [11]. Stu-
dies have reported the potential use of sophisticated
techniques such as sequencing to detect drug resistance
mutations which can serve as epidemiological markers,
since the relative frequency of alleles associated with resis-
tance varies geographically [12-14]. The application of the
GenoType MTBDRplus assay has been reported in other
high burden settings such as Russia, South Africa and
China, but has not yet been reported from our setting
[10,15,16].
Despite guidelines that advocate DST for patients failing
any treatment regimen [17], it is only performed in 0.5%
of notified previously treated TB cases [1]. The endemic
setting of Mumbai with reports of increasing levels of
MDRTB [18-21] and a high case load would benefit from
the introduction of molecular methods to detect resis-
tance, overcoming the drawbacks of culture methods.
This study was therefore undertaken to evaluate the
MTBDRplus for detection of MDR, defined as resistance
to at least INH and RIF, in pulmonary TB (PTB) patients
in Mumbai. The dual objectives thus encompassed deter-
mination of the nature and frequency of mutations asso-
ciated with resistance and correlations, if any, between the
type of mutation and treatment outcome of the patient.
Additionally, the assay enabled the detection of heterore-
sistance to both INH and RIF.
Methods
Location and patient selection
This study was carried out on isolates from sputum sam-
ples collected from April 2004 to September 2007, for an
epidemiological project on MDRTB transmission in Mum-
bai [18]. Samples were collected at onset and fifth month
of treatment from patients registered with the DOTS
(Directly Observed Therapy Short Course) Centers of the
RNTCP (Revised National Tuberculosis Control Pro-
gramme) in 4 centrally located wards, characterized by a
high sputum positive case load and covering a population
of 3 million. Patients were sputum smear positive, within
the 15-70 yr age group, and commenced on 2 months of
isoniazid, rifampicin, pyrazinamide and ethambutol fol-
lowed by 4 months of isoniazid and rifampicin, each phase
thrice weekly. To minimize bias towards MDR, patients
with no history of TB or antitubercular therapy, and those
with no interruption of treatment or interruption for < 2
weeks, were included after informed consent. Clearance
for the parent study was obtained from the Foundation for
Medical Research (FMR) Institutional Ethics Committee
(20.07.2001/01).
A total of 681 onset and 345 fifth month samples were
collected for the parent study. A convenience subset com-
prising of 88 onset and 67 fifth month samples covering
different susceptibility profiles was used for this analysis.
Drug susceptibility testing
Early morning samples were processed by the modified
Petroff’s method [22], stained by Ziehl-Neelsen Carbol
Fuchsin, microscopically examined, and cultured on Low-
enstein-Jensen (LJ) slopes (Himedia, India) and in Dubos
broth (Himedia, India). Biochemical tests for niacin and
catalase production were performed to confirm the iden-
tity of M. tb. DST was performed by the radiorespiro-
metric Buddemeyer technique (a modification of the
Bactec 460 technique) as described earlier [18,23,24] for
the following drugs (μg/ml): Isoniazid (0.1), Rifampicin (2),
Pyrazinamide (PZA-100) and Ethambutol (ETB-2.5).
MDR was defined as resistance to at least INH and RIF.
Other cases were categorized as: sensitive - absence of
resistance to any drug, monoresistance - resistance to only
1 drug and polyresistance - resistance to two or three
drugs excluding the INH-RIF combination.
External quality control of phenotypic DST
Ten percent of the isolates from the parent study were
sent single blinded to the Swedish Institute for Infectious
Disease Control, Stockholm, a WHO/International
Union Against Tuberculosis and Lung Disease (IUATLD)
supranational reference laboratory for external quality
assurance by the Bactec 460 method. Kappa scores
showed excellent agreement (range 0.76-0.77), for INH
and RIF [18].
The GenoType MTBDRplus assay (Hain Lifesciences,
Germany)
DNA for the assay was extracted from bacilli grown on
LJ media by the cetyl trimethyl ammonium bromide
(CTAB) and chloroform isoamyl alcohol method [25].
The assay was performed according to the manufac-
turer’s instructions. The test is based on DNA strip
technology comprising multiplex PCR amplification and
reverse hybridization.
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Each strip consists of 27 reaction zones (bands), including
6 controls (conjugate, amplification, M. tb complex, rpoB,
katG,a n dinhA controls), 8 rpoB wild-type [WT1-WT8
(506-509, 510-513, 513-517, 516-519, 518-522, 521-525,
526-529 and 530-533)] and 4 mutants [MUT1, 2A, 2B and
3 (D516V, H526Y, H526D and S531L)], 1 katG WT (315)
and 2 mutants [MUT1 and 2 (S315T1 and S315T2)] and 2
inhA WT [WT1 and 2 (-15/-16 and -8)] and 4 mutants
[MUT1, 2, 3A and 3B (C15T, A16G, T8C and T8A)].
In general for the 3 loci, a pattern comprising only WT
bands was interpreted as sensitive. Resistance was inter-
preted as: i) absence of 1/more WT bands ii) presence of
mutant bands with or iii) without the simultaneous
absence of the complementary WT. The simultaneous
presence of WT and corresponding mutant bands was
referred to as a mixed pattern.
Data analysis
Patterns of RIF and INH resistance in MDRTB and non
MDRTB isolates were analysed. The ability of RIF resis-
tance alone to predict MDR was also investigated. Results
obtained through phenotypic DST and the GenoType
MTBDRplus were compared for RIF, INH and MDR and
kappa scores were generated for concordance. The inter-
pretations were: < 0.45 = Poor, 0.45 - 0.70 = Fair and >
0.70 = Excellent [26]. The Chi square test using EpiInfo
2002 was used to determine association between para-
meters and a p-value of ≤ 0.05 was considered significant.
Results
Phenotypic DST
Amongst the 88 onset isolates, 41 (47%) were sensitive, 20
(23%) monoresistant (11 INH, 2 RIF, 2 PZA and 5 ETB),
18 (20%) MDR, and the remainder 9 polyresistant (10%).
Amongst the 67 fifth month isolates, none were sensitive
or monoresistant, 60 (90%) were MDR and 7 (10%) were
polyresistant.
Genotypic DST
Of the 88 onset isolates, 46 (52%) were sensitive, 20 (23%)
only INH resistant, 2 (2%) only RIF resistant and 20 (23%)
MDR. Of the 67 fifth month isolates 1 (1.5%), 2 (3%), 2
(3%) and 62 (92.5%) were sensitive, only INH resistant,
only RIF resistant and MDR respectively.
Comparison of the Buddemeyer and GenoType
MTBDRplus assays
Excellent agreement was obtained between the 2 methods
for the onset, fifth month and combined isolates for INH
and RIF as represented in Table 1.
A total of 73 (83%) onset and 64 (96%) fifth month iso-
lates showed concordant DST profiles for INH and RIF
(Table 2). A comparison of the genotypic versus
phenotypic assays at onset revealed 7 isolates which were
INH resistant and RIF sensitive by the GenoType
MTBDRplus assay but INH and RIF sensitive by the Bud-
demeyer assay. Additionally, 2 isolates were INH and
RIF sensitive by the GenoType MTBDRplus assay
but INH resistant and RIF sensitive by the Buddemeyer
assay (Table 2). Of 4 isolates identified MDR by the
MTBDRplus, 3 were phenotypically only INH resistant,
while 1 was only RIF resistant. Amongst the fifth month
isolates, discordance was noted in 3 isolates identified as
MDR by the MTBDRplus, wherein the Buddemeyer
detected 1 to be only INH resistant and 2 to be only RIF
resistant.
Mutations identified using the GenoType MTBDRplus
assay
The frequency of mutations detected in the 3 genes is
described in Table 3.
RpoB
Twenty-two onset and 64 fifth month isolates showed
resistance. For the onset isolates, the most frequent muta-
tion was the absence of only WT8 (n = 8). A further 4 iso-
lates showed the corresponding S531L mutation. Mixed
patterns for D516V were seen in 9 isolates. Of the fifth
month isolates, the most frequent mutations were in
codons 530-533 (n = 31), wherein 26 showed the absence
of WT8 alone; or in combination with absence of WT6, 7
(n = 2); WT7 (n = 2) or WT1, 6 (n = 1). A further 9 iso-
lates showed the corresponding S531L mutation. Only 1
isolate showed a H526Y mutation. Mixed patterns were
seen in 22/64 isolates (34%), the most frequent for the
D516V mutation (n = 21). For those WT bands with a
corresponding mutant band (WT 3, 4, 7 and 8), loss of
WT only was seen in 9 onset and 40 fifth month isolates.
KatG
Resistance was detected in 22 onset and 35 fifth month
isolates. Lack of the wild type with the presence of the
S315T1 mutation were seen in 13 onset and 12 fifth
month isolates, of which 9 and 7 respectively also showed
the S315T2. Mixed patterns involving both mutations
were seen in 9 and 23 isolates respectively. Amongst onset
isolates, an association was noted between katG mutations
and resistance to ethambutol (c
2 =8 . 6 3 ,p = 0.0033).
Table 1 Concordance between genotypic (MTBDRplus
assay) and phenotypic (Buddemeyer assay) resistance
Sample INH RIF
%
Concordance
kappa %
Concordance
kappa
Onset (n = 88) 86 0.72 94 0.84
5th month (n = 67) 97 0.74 99 0.85
Cumulative (n =
155)
91 0.80 96 0.92
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Of 23 isolates resistant at onset, 3 each showed either only
absence of WT2 or the C15T mutation. Seventeen showed
m i x e dp r o f i l e sf o rA 1 6 G .O f3 5i solates resistant at fifth
month, 10 lacked the WT2, while 23 had a mixed profile
for A16G, of which 1 had a mixed profile even for T8A.
Loss of WT only was seen in 3 onset and 10 fifth month
isolates.
Analysed collectively, 40 onset and 64 fifth month iso-
lates showed INH resistance. Of these, 17 onset (43%) and
29 fifth month (45%) isolates showed resistance only
through katG while in both groups an equivalent propor-
tion [45% (18 onset and 29 fifth month)] were resistant
only through inhA. The remaining 5 onset and 6 fifth
month isolates had mutations in both genes.
Overall, 46 onset and only 1 fifth month isolate were
s e n s i t i v et oI N Ha n dR I F .O f1 8o n s e ta n d4f i f t h
month isolates resistant to only INH, 2 onset isolates
had dual mutations in katG and inhA, while the
remainder had mutations in either 1. No fifth month
isolates had such dual mutations. Two isolates each
among the onset and fifth month isolates were resistant
to only RIF (Table 3).
Of the 82 MDR isolates (20 onset and 62 fifth month),
the predominant patterns involved absence of WT8 with
either S315T1/2 or Δ-8 mutations (Table 3). No associa-
tion was found between a particular mutation and a
monoresistant or MDR profile.
An analysis of the profiles for all 3 genes revealed that a
significant number of fifth month isolates had mixed pro-
files in comparison to onset isolates (c
2 = 23.75, p =
0.000001). For katG, an association (p = 0.0012) was noted
between a clean resistant profile (as against a mixed pro-
file) and poor outcome (death or treatment failure). Simi-
larly an association was noted between only katG
resistance (as against only inhA resistance) and poor out-
come (c
2 = 4.37, p = 0.037). Cure was associated with
A16G (p = 0.02) and Δ-8 (p =0 . 0 1 5 )i nc o m p a r i s o nt oa
C15T mutation in the inhA.
Rifampicin resistance as an indicator of MDRTB
Of the 23 isolates showing RIF resistance at onset by the
MTBDRplus,2w e r eo n l yR I Fr e s i s t a n t ,w h i l s tt h e
remainder were MDR. Of the fifth month isolates, 62/64
RIF resistant isolates were MDR.
Discussion
To the best of our knowledge this is the first study from
this setting to investigate genotypic profiles in the rpoB,
katG and inhA regions associated with DR using the
MTBDRplus assay. Techniques which detect MDR muta-
tions in new cases at onset or during therapy would enable
rapid identification of MDR and facilitate the modification
of regimens with improvement to programme practices.
Overall, the concordance between the methods for INH
and RIF ranged from 86-97% and 94-99% respectively. Fif-
teen discordant results were obtained for INH resistance,
of which 5 were phenotypically resistant but genotypically
sensitive, possibly because the mutations lie outside the
regions covered by the probes. Ten discordant results
were Buddemeyer sensitive but MTBDRplus resistant,
wherein 5 were inhA mutants, known to be associated
with low level resistance [27]. Of the remainder, 4 were
onset isolates with katG mutations, of which 2 showed a
mixed profile. This may explain the phenotypic sensitivity
despite the katG mutations being associated with high
level resistance [27]. The remainder 2 profiles showed the
katG S315T1 mutation but were INH sensitive by the
Buddemeyer. For one of these isolates, the interpretation
of the drug susceptibility could have altered from sensitiv-
ity to resistance on extended incubation. For the second
isolate, there was no indication of resistance and the dis-
cordance could reflect a technical anomaly in the phenoty-
pic assay, or an “adaptation” by the strain which has
prevented phenotypic expression of the katG mutation.
Of 5 isolates that were MTBDRplus RIF resistant but
Buddemeyer sensitive, 4 lacked the WT8 band, including
3 which showed the MUT3 (S531L). Though associated
with high level resistance, its detection at onset could
Table 2 Comparison of the MTBDRplus assay with conventional drug susceptibility testing at onset and 5th month
GENOTYPIC DST
PHENOTYPIC DST INH
s RIF
s INH
r RIF
s INH
s RIF
r INH
r RIF
r
Onset (n = 88) INH
s RIF
s 4 3 700
INH
r RIF
s 21 3 03
INH
s RIF
r 0011
INH
r RIF
r 1011 6
5th month (n = 67) INH
s RIF
s 1000
INH
r RIF
s 0201
INH
s RIF
r 0012
INH
r RIF
r 0015 9
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Pattern rpoB katG inhA n (onset) n (5th month)
Only INH (n = 22) - - A16G mixed 6 1
- S315T1 - 3 1
-- ΔWT2 2 0
- - C15T 2 0
- S315T1, T2 - 2 0
- S315T1, T2 mixed - 2 0
- S315T1, T2 A16G mixed 1 0
- S315T1 mixed - 1 0
- S315T1, T2 mixed A16G mixed 1 0
Only RIF
(n = 4)
Δ WT8 - - 1 1
ΔWT6, 7, 8 - - 0 1
D516V mixed - - 1 0
MDR
(n = 82)
ΔWT8 S315T1, T2 mixed - 2 11
D516V mixed - A16G mixed 4 5
ΔWT8 - ΔWT2 1 6
ΔWT8 - A16G mixed 3 4
S531L S315T1 - 1 4
D516V mixed, ΔWT8 - A16G mixed 0 4
S531L S315T1, T2 mixed - 1 3
D516V mixed, S531L S315T1, S315T2 - 0 3
ΔWT8 S315T2 mixed - 1 1
ΔWT7, 8 - ΔWT2 0 2
D516V mixed, ΔWT8 S315T1, T2 mixed A16G mixed 0 2
D516V mixed, ΔWT8 S315T1, T2 mixed - 0 2
D516V mixed S315T1, S315T2 A16G mixed 1 1
ΔWT8 S315T1, S315T2 - 0 1
ΔWT4 S315T1, S315T2 - 1 0
ΔWT8 - C15T mixed 0 1
ΔWT8 S315T1 mixed - 0 1
ΔWT7 - ΔWT2 0 1
ΔWT6, 7, 8 - ΔWT2 0 1
ΔWT1, 6, 8 - A16G mixed 0 1
H526Y S315T1, S315T2 - 0 1
S531L S315T1, S315T2 C15T 1 0
S531L S315T1, S315T2 - 1 0
D516V mixed, S531L S315T1, T2 mixed - 1 0
D516V mixed, S531L S315T1, S315T2 A16G mixed 1 0
D516V mixed, S531L - C15T 0 1
S531L S315T1, S315T2 A16G mixed 0 1
S531L - A16G mixed 0 1
D516V mixed, S531L S315T1, T2 mixed A16G mixed 0 1
D516V mixed, S531L S315T2 mixed - 0 1
D516V mixed, S531L - A16G mixed 0 1
D516V mixed S315T1, S315T2 - 1 0
S531L mixed S315T1, T2 mixed A16G mixed, T8A 0 1
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resistance which may remain undetected despite conven-
tional DST has been previously reported [28,29].
Heteroresistance, reflecting the slow evolution of bac-
teria from a sensitive to resistant profile, is not uncommon
in M. tb [30]. However our study is probably the first to
report relatively high levels of heteroresistance in all 3
genes in an endemic setting. Two explanations are offered
for this finding. Firstly, heteroresistance could have arisen
due to transmission of both susceptible and resistant bac-
terial populations from drug resistant patients to pre-
viously untreated cases. An endemic setting like Mumbai
would be prone to the prevalence of MDR strains, and
hence new cases, even at onset, are likely to harbour resis-
tant bacteria at proportions genotypically detectable but
phenotypically undetectable, as suggested by the detection
of mixed profiles in our onset isolates [31]. Studies on het-
eroresistance have shown that phenotypic DST results
corresponded to the mutated, i.e. resistant, organism [31].
Secondly, the presence of exclusively sensitive bacteria at
onset which gradually develop resistance during therapy,
with incomplete elimination of the sensitive population by
fifth month, would result in phenotypic resistance but
with both forms remaining detectable genotypically. This
possibility has been explained through mathematical mod-
elling of the scenario in which MDR bacilli arise from a
completely sensitive original infection [32]. The second
scenario may explain the higher occurrence of mixed pat-
terns among our fifth month isolates in comparison to the
onset isolates. The probability of any bias towards detec-
tion of heteroresistance has been reduced by excluding
patients with various other likely contributory factors such
as prior treatment and defaulting. DNA fingerprinting
techniques such as Mycobacterial Interspersed Repetitive
Units Variable Number Tandem repeats (MIRU VNTR)
would help gauge whether multiple infections have con-
tributed to the heteroresistance detected.
The detection of heteroresistance seems to support our
finding of an association between a clean resistant profile
for the katG and a poor outcome, since the presence of
exclusively resistant strains is more likely to result in non
responsiveness to treatment. Identification of hetereoresis-
tance can be used to probe outcomes of smear examina-
tion based “cure” s i n c em i c r o s c o p ym a yn o tb es e n s i t i v e
enough to detect a small focus of bacteria which have
evolved from sensitivity to resistance during therapy.
INH resistance can develop through mutations in the
inhA open reading frame (ORF) (0-5%) or the promoter
(8-20%). Between 40 to 95% of INH resistant isolates
have mutations in katG, 75-90% of which are in codon
315, with 10-25% in other loci [33]. The frequency of the
katG S315T substitution in M. tb strains varies globally
in relation to the prevalence of TB: from 26-30% in
regions with intermediate/low prevalence [34] upto 91%
of strains in Russia [35]. Most reports reveal higher levels
of katG mutations in comparison to the inhA mutations,
viz. 73% and 22% [36], 46% and 27% [37], 64% and 42%
[10] respectively. However we detected nearly equivalent
levels of katG - 55% at onset and fifth month; and inhA -
58% onset and 55% fifth month in concurrence with
Lacoma et al. [27]. We found dual mutations in katG and
inhA in 12.5% and 9% of onset and fifth month isolates,
comparable to the 3-13% reported elsewhere [2,15,38].
Mutations in katG 315 may be favoured because they
decrease INH activation without abolishing catalase-perox-
idase activity, reflecting its low fitness cost [11,33,39-41].
The detection of equal proportions of katG and inhA
mutations indicate that in our setting, inhA may also have
a low fitness cost. This may be a consequence of the
extended occurrence of MDR allowing for acquisition of
compensatory mutations such as in the ahpC [42]. Despite
their equivalent levels, katG but not inhA mutations, were
associated with treatment failure.
Our data identified associations between katG 315
mutations and ethambutol resistance as well as poor out-
come. It has been reported that the iniBAC promoter is
induced by cell wall biosynthesis inhibitors such as isonia-
zid and ethambutol [43]. Overexpression of the iniA gene
confers a tolerance-like phenotype to INH and ETB.
Furthermore, the iniA gene product is an essential compo-
nent of an MDR-like pump [44]. Resistance to INH
through katG mutations might influence response to
other drugs, allowing development of resistance to etham-
butol [45] and streptomycin [46], leading to poor treat-
ment response.
Of the 86 RIF resistant isolates, 70 showed a mutation in
the 530-533 region of the rpoB. However only 23 (27%)
showed the specific S531L mutation as compared to other
studies reporting 46-79% of strains with this mutation
[10,27,36,37]. The low fitness cost of rpoB S531L [47] may
account for its high frequency in these regions (i.e. South
Africa, France, Spain) though its occurrence has also been
reported to be as low as 30-31% in India and Hungary
[12,48]. The lower proportion of the S531L compared to
the D516V mutation indicates that the latter is also not
associated with a fitness cost, at least in our setting.
Our study failed to find any association between a parti-
cular mutation and the occurrence of monoresistance or
MDR. However, other studies have reported a significantly
higher level of katG and S531L mutations in MDR isolates
compared to INH or RIF monoresistant isolates respec-
tively [10,38]. It is likely that this difference is due to the
relatively low occurrence of S531L and the equivalent pro-
portions of katG and inhA mutations in our cohort.
The value of RIF as a surrogate MDR marker has been
documented [49] and further corroborated in our study.
Despite their advantages, genotypic methods do not
always identify phenotypically resistant strains [38],
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for supplementation with culture or additional probes.
Additionally resistance can be inferred from the absence
of a wild type signal alone, without confirmation by a
mutant probe signal (in 47% of our isolates) and may be
due to a mutation in a region not associated with resis-
tance [29]. Such susceptible isolates would be called
resistant leading to the unnecessary removal of RIF and/
or INH from therapy. Moreover since a proportion of
INH resistance, particularly in monoresistant isolates,
could be due to resistance determinants other than katG
S315T and inhA C15T, these isolates would also be indi-
cated as susceptible. This highlights the need for the
interpretation of genotypic data in conjunction with
patient clinical status and the determination of mutations
specific to certain geographical locales.
Conclusions
Despite the limitations of the MTBDRplus assay, its
rapidity and sensitivity still favour its implementation as
an initial screen for MDRTB. The presence of resistance
mutations and the occurrence of heteroresistance could
not only guide the need for simultaneously initiating
first- and second-line DST, but also significantly reduce
the delay in administering an appropriate regimen to an
MDR (or extensively drug resistant) TB case.
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